The US drug industry may need to lower its expectations about the number and variety of additional OTC drug formulations and indications becoming available in the US through the Food and Drug Administration’s overhauled monograph program.
Food and drug attorneys pointed out during a recent Food and Drug Law Institute online conference that even with the program becoming more efficient and predictable under reform authorized by Congress, firms will need to invest in research and studies to support proposals for monograph additions or changes and pay user
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?